Literature DB >> 27439000

Increasing survival from leukemia among adolescents and adults in Canada: A closer look.

Larry F Ellison1.   

Abstract

BACKGROUND: Survival from adult onset leukemia has increased substantially in Canada since at least the early 1990s. However, an analysis of the extent of this improvement by type of leukemia is lacking. DATA AND METHODS: Data are from the Canadian Cancer Registry, with mortality follow-up through record linkage to the Canadian Vital Statistics Death Database. Increases in five-year relative survival ratios (RSRs) between 1992-to-1994 and 2006-to-2008 were calculated by age and sex for all leukemias combined and for each of the main types.
RESULTS: Increases in five-year RSRs were significant for all leukemia types studied, ranging from 9.2 percentage units for acute myeloid leukemia (AML) to 24.9 percentage units for chronic myeloid leukemia (CML). For all leukemias combined, additional adjustment for case-mix reduced the increase in survival from 14.6 to 11.8 units; increases were significant among both sexes and each age group. Improvement in survival for chronic lymphocytic leukemia (CLL) was greater at older ages. For AML, improvements were greater among people younger than age 55; no significant change was detected among those diagnosed at ages 75 to 99. A significant survival advantage for women relative to men was apparent in the 2006-to-2008 period for all leukemias combined and for CLL and CML.
INTERPRETATION: Despite recent significant gains in survival for each main type of leukemia, room remains for improvement.

Entities:  

Keywords:  Acute lymphoblastic leukemia; acute myeloid leukemia; chronic lymphoblastic leukemia; chronic myeloid leukemia; neoplasms; population-based; registries; relative survival; survival analysis

Mesh:

Year:  2016        PMID: 27439000

Source DB:  PubMed          Journal:  Health Rep        ISSN: 0840-6529            Impact factor:   4.796


  4 in total

1.  Improved outcome for AML patients over the years 2000-2014.

Authors:  Sarah Bertoli; Suzanne Tavitian; Anne Huynh; Cécile Borel; Sarah Guenounou; Isabelle Luquet; Eric Delabesse; Audrey Sarry; Guy Laurent; Michel Attal; Françoise Huguet; Emilie Bérard; Christian Récher
Journal:  Blood Cancer J       Date:  2017-11-29       Impact factor: 11.037

Review 2.  Natural Health Products (NHP's) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer; Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends.

Authors:  Benjamin Scaria; Siddhartha Sood; Christopher Raad; Jana Khanafer; Rahul Jayachandiran; Alaina Pupulin; Sahibjot Grewal; Michael Okoko; Mansi Arora; Lauren Miles; Siyaram Pandey
Journal:  Int J Mol Sci       Date:  2020-11-11       Impact factor: 5.923

Review 3.  A narrative review of central nervous system involvement in acute leukemias.

Authors:  Dalma Deak; Nicolae Gorcea-Andronic; Valentina Sas; Patric Teodorescu; Catalin Constantinescu; Sabina Iluta; Sergiu Pasca; Ionut Hotea; Cristina Turcas; Vlad Moisoiu; Alina-Andreea Zimta; Simona Galdean; Jakob Steinheber; Ioana Rus; Sebastian Rauch; Cedric Richlitzki; Raluca Munteanu; Ancuta Jurj; Bobe Petrushev; Cristina Selicean; Mirela Marian; Olga Soritau; Alexandra Andries; Andrei Roman; Delia Dima; Alina Tanase; Olafur Sigurjonsson; Ciprian Tomuleasa
Journal:  Ann Transl Med       Date:  2021-01

4.  Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Authors:  Christian Récher; Christoph Röllig; Arnaud Pigneux; Pau Montesinos; Emilie Bérard; Sarah Bertoli; Pierre-Yves Dumas; Suzanne Tavitian; Michael Kramer; Hubert Serve; Martin Bornhäuser; Uwe Platzbecker; Carsten Müller-Tidow; Claudia D Baldus; David Martínez-Cuadrón; Josefina Serrano; Pilar Martínez-Sánchez; Eduardo Rodríguez Arbolí; Cristina Gil; Juan Bergua; Teresa Bernal; Adolfo de la Fuente Burguera; Eric Delabesse; Audrey Bidet
Journal:  Leukemia       Date:  2021-11-13       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.